Edition:
United Kingdom

People: Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

9.71USD
23 Aug 2019
Change (% chg)

$-0.27 (-2.71%)
Prev Close
$9.98
Open
$9.96
Day's High
$10.00
Day's Low
$9.55
Volume
43,519
Avg. Vol
56,433
52-wk High
$17.80
52-wk Low
$9.23

Aldrich, Richard 

Mr. Richard H. Aldrich is an Independent Chairman of the Board, Co-Founder of Concert Pharmaceuticals Inc. Mr. Aldrich is a co-founder and has been a Partner of Longwood Fund, a venture capital firm, since December 2010. Mr. Aldrich has been an employee of Longwood Management LLC since August 2015. Mr. Aldrich founded RA Capital Management LLC, a hedge fund, in 2001 and served as a Managing Member from 2001 to 2008 and as a Co-Founding Member from 2008 until 2011. Mr. Aldrich has co-founded and helped to build several biotechnology companies including Sirtris Pharmaceuticals, Inc., (acquired by GlaxoSmithKline in 2008), Alnara Pharmaceuticals, Inc. (acquired by Eli Lilly in 2010), Verastem, Inc., OvaScience, Inc. and Flex Pharma, Inc. Mr. Aldrich was also a founding employee of Vertex Pharmaceuticals Incorporated, where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen Inc. Mr. Aldrich also serves on the boards of a number of private biotechnology companies. During the last five years, Mr. Aldrich also served as a member of the board of directors of PTC Therapeutics, Inc. and Verastem, Inc., both of which are public biopharmaceutical companies, as well as OvaScience, Inc., a public biopharmaceutical company at the time of its merger with Millendo Therapeutics, Inc. in 2018. Mr. Aldrich received his B.S. in Management from Boston College and an M.B.A. from the Amos Tuck School at Dartmouth College. We believe Mr. Aldrich’s broad-based experience in business, including his leadership and board experience at life science companies, and his familiarity with our business as a co-founder of our company allow him to be a key contributor to our Board of Directors.

Basic Compensation

Total Annual Compensation, USD 71,865
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 133,748
Fiscal Year Total, USD 205,613

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Aldrich

205,613

Roger Tung

4,607,850

Marc Becker

2,450,530

Nancy Stuart

1,908,030

James Cassella

1,960,240

Thomas Auchincloss

205,613
As Of  31 Dec 2018